AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31328281
Drug: Family-focused cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-focused cognitive behavioral treatment (F-CBT)
Trial: 23173830
Drug: Enhanced treatment-as-usual
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced treatment-as-usual (E-TAU)
Trial: 28894075
Drug: Chlorhexidine solution
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 99.0 g in 1 L TOPICAL SOLUTION [CHLORHEXIDINE Solution]
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine solution (0.12% dilution)
Trial: 19735563
Drug: Physical Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical Therapy exclusively with standardized protocols
Trial: 19735563
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with Shoulder Dynasplint and standardized Physical Therapy
Trial: 15209578
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 1000 mg PO 1 hour before cath/PCI and 4 hours later
Trial: 11755455
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 300 microg of CNP
Trial: 9520616
Drug: Methimazole treatment
RxNorm normalized name: Methimazole
DrugBank: Methimazole (DB00763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methimazole treatment for 11.2 ± 1.0 weeks
Trial: 7975860
Drug: Plasma-derived vaccine
RxNorm normalized name: Haptoglobulin 1/1 (Plasma Derived)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma-derived vaccine (Hevac B)
Trial: 7975860
Drug: Recombinant HBsAg
RxNorm normalized name: HBSAG
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant HBsAg vaccine (Engerix-B)
Trial: 3132383
Drug: roxithromycin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: roxithromycin (150 mg 2 X day)
Trial: 3132383
Drug: cephradine (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cephradine (1.0 g 2 X day)
Trial: 31230261
Drug: Tadalafil 5
RxNorm normalized name: tadalafil 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 5 mg + Aspirin 100 mg
Trial: 28463849
Drug: Febuxostat (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Febuxostat (40 mg thrice weekly)
Trial: 25416737
Drug: Mirror therapy-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirror therapy-based action observation (AO) group
Trial: 23353589
Drug: Spinal anesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anesthesia followed by intravenous morphine analgesia (Group A)
Trial: 21533031
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination ART
Trial: 16483745
Drug: Aripiprazole (initiated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (initiated at 15 mg/d, adjusted between 10-30 mg/d)
Trial: 16483745
Drug: Safety Control
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safety Control (another antipsychotic medication, dosed according to prescribing guidelines)
Trial: 9165611
Drug: Alarm plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alarm plus 40 micrograms desmopressin (Minirin, DDAVP) nasal spray
Trial: 16140092
Drug: Alarm monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alarm monotherapy
Trial: 27163250
Drug: Mobile upper
RxNorm normalized name: Chamaemelum nobile extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile upper extremity rehabilitation program (MoU-Rehab) combined with conventional occupational therapy (OT)
Trial: 27163250
Drug: Conventional occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional occupational therapy (OT) alone
Trial: 22815078
Drug: STAM‐Dem protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STAM‐Dem protocol (2 weekly sessions of 45 minutes for 12 weeks)
Trial: 20133918
Drug: 0.9 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 mg/kg IV tissue plasminogen activator within 3 hours of symptom onset
Trial: 17853158
Drug: 200 microg
RxNorm normalized name: Digoxin 200 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 microg sublingual misoprostol 2 hours prior to the procedure
Trial: 2208022
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF)
Trial: 31227019
Drug: Misoprostol (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol (400 μg administered sublingually every 3 hours up to five doses within 24 hours)
Trial: 28513179
Drug: Watermelon juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Watermelon juice enriched with l-Citrulline and pomegranate ellagitannins
Trial: 24101149
Drug: Oral anticoagulation
RxNorm normalized name: monitoring agent for oral anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulation (OAC) discontinued after successful AF ablation; average 7.3 months follow-up off OAC.
Trial: 2651016
Drug: Tizanidine (max.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tizanidine (max. 20 mg/day)
Trial: 2651016
Drug: Baclofen (max.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen (max. 50 mg/day)
Trial: 340132
Drug: Tinidazole (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinidazole (2 g once daily for 3 days)
Trial: 340132
Drug: Metronidazole (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (2 g once daily for 3 days)
Trial: 31109201
Drug: Esketamine nasal
RxNorm normalized name: esketamine Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esketamine nasal spray (56 or 84 mg twice weekly) plus newly initiated antidepressant
Trial: 31109201
Drug: Esketamine nasal
RxNorm normalized name: esketamine Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esketamine nasal spray plus antidepressant
Trial: 21311345
Drug: Concurrent training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent training (CG)
Trial: 19685935
Drug: Hypotonic PEG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypotonic PEG (12 g once or twice daily or once every other day for 4 weeks)
Trial: 19685935
Drug: Isotonic PEG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic PEG (12 g once or twice daily or once every other day for 4 weeks)
Trial: 12020142
Drug: Alendronate, 10
RxNorm normalized name: Alendronate, 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate, 10 mg/d
Trial: 17074112
Drug: Tibolone, 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone, 1.25 mg/d
Trial: 17074112
Drug: Calcium preparation
RxNorm normalized name: oyster shell calcium carbonate preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium preparation only
Trial: 9024732
Drug: 15 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g/day supplemental water‐soluble dietary fiber (WSDF; a mixture of psyllium, pectin, guar gum, and locust bean gum)
Trial: 8388352
Drug: Low-molecular-weight heparins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparins administered subcutaneously
Trial: 29890086
Drug: Azithromycin (3×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (3× weekly) with standardized tobramycin inhalation solution (TIS)
Trial: 29890086
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with standardized tobramycin inhalation solution (TIS)
Trial: 23419913
Drug: Multimodal physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal physical therapies
Trial: 21170106
Drug: Alprostadil cream
RxNorm normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alprostadil cream 500 μg
Trial: 21170106
Drug: Alprostadil cream
RxNorm normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alprostadil cream 700 μg
Trial: 21170106
Drug: Alprostadil cream
RxNorm normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alprostadil cream 900 μg
Trial: 11334057
Drug: PEG‐rHuMGDF at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐rHuMGDF at a dose of 5.0 microg/kg/day
Trial: 8803380
Drug: Fentanyl citrate,
RxNorm normalized name: FentaNYL Citrate, compounding powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl citrate, hydromorphone hydrochloride, methadone hydrochloride, and morphine sulfate solutions
Trial: 6402914
Drug: Nifedipine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (30 to 60 mg/day orally)
Trial: 23116022
Drug: Immunomodulator Lavomax
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunomodulator Lavomax and basic treatment: azithromycin (1.0 g once a week for 3 weeks), Celebrex, physiotherapy (low‐intensity laser radiation), prostate massage
Trial: 14619336
Drug: Steroid resistant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid resistant (SR) patients
Trial: 14619336
Drug: Steroid sensitive
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid sensitive (SS) patients
Trial: 8683967
Drug: 1.00 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.00 g/kg alcohol dose
Trial: 21138709
Drug: 0.25 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 g/kg alcohol dose
Trial: 8683967
Drug: 0.50 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.50 g/kg alcohol dose
Trial: 2003373
Drug: Acupuncture twice
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture twice a week for two months
Trial: 6342554
Drug: 2.5% albumin‐lactated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5% albumin‐lactated Ringer's solution
Trial: 30852854
Drug: Intimacy-enhancing therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intimacy-enhancing therapy (IET)
Trial: 29600580
Drug: Acitretin (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acitretin (0.4 mg/kg per day) plus nanocurcumin (3 g/day)
Trial: 21913224
Drug: Safinamide 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safinamide 200 mg
Trial: 21913224
Drug: Safinamide 100
RxNorm normalized name: safinamide 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safinamide 100 mg
Trial: 10861157
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg intramuscular midazolam
Trial: 3572102
Drug: Levamisole as
RxNorm normalized name: Levamisole
DrugBank: Levamisole (DB00848)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levamisole as an immuno-stimulator for 1 year along with chemotherapy
Trial: 30502984
Drug: Subcutaneous tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous tranexamic acid (TXA)
Trial: 22520084
Drug: Vilanterol 6.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vilanterol 6.25 mcg once-daily
Trial: 22520084
Drug: Vilanterol 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vilanterol 12.5 mcg once-daily
Trial: 22520084
Drug: Vilanterol 25
RxNorm normalized name: FLUTIC 50/VILANTEROL 25MCG 30D ORAL INH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vilanterol 25 mcg once-daily
Trial: 22520084
Drug: Vilanterol 6.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vilanterol 6.25 mcg twice-daily
Trial: 1916007
Drug: 1 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g/day alpha‐glycerylphosphorylcholine (alpha‐GPC)
Trial: 1916007
Drug: 1 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g/day cytosine diphosphocholine (CDP)
Trial: 30969960
Drug: Praziquantel from
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Praziquantel from Nanjing Pharmaceutical Factory (NPF), China
Trial: 23831177
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual combined with animal-assisted therapy (AAT) administered over 10 weekly sessions
Trial: 20024643
Drug: BNP concentration
RxNorm normalized name: BNP
DrugBank: Nesiritide (DB04899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BNP concentration > 50 pg/ml
Trial: 20024643
Drug: BNP concentration
RxNorm normalized name: BNP
DrugBank: Nesiritide (DB04899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BNP concentration median 11.3 pg/ml
Trial: 17663620
Drug: Cognitive-behavioral group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral group therapy for 2 months
Trial: 31752976
Drug: Combination antimicrobial
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination antimicrobial therapy
Trial: 10189538
Drug: 5.07/10-g monofilament
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.07/10-g monofilament at five sites on the right foot
Trial: 10189538
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of sites 3 and 4 for monofilament testing
Trial: 10189538
Drug: Monofilament with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monofilament with buckling force of 5 g and 15 g
Trial: 7754764
Drug: alkylated immunoglobulin
RxNorm normalized name: petroleum alkylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alkylated immunoglobulin G intravenous preparation (IGIV) 200 mg/kg daily x 3 days + aspirin
Trial: 7754764
Drug: alkylated immunoglobulin
RxNorm normalized name: petroleum alkylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alkylated immunoglobulin G intravenous preparation (IGIV) 400 mg/kg daily x 3 days + aspirin
Trial: 7754764
Drug: native IGIV
RxNorm normalized name: IGIV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: native IGIV 200 mg/kg daily x 5 days + aspirin
Trial: 7754764
Drug: native IGIV
RxNorm normalized name: IGIV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: native IGIV 400 mg/kg daily x 5 days + aspirin
Trial: 8704439
Drug: Longevity-Antihypertensive-Mixture (LAM)
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longevity-Antihypertensive-Mixture (LAM)
Trial: 2148508
Drug: Apocyhum Venetum
RxNorm normalized name: Apocynum cannabinum root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apocyhum Venetum L. Fluid (AVLF)
Trial: 6945046
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg PGE2 for primigravidas
Trial: 6945046
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg PGE2 for multigravidas
Trial: 6945046
Drug: Conventional induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional induction by amniotomy and immediate oxytocin titration
Trial: 30502372
Drug: Ranibizumab 0.5
RxNorm normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab 0.5 mg monthly until complete resolution of SRF and IRF (intensive arm: SRF intolerant)
Trial: 30502372
Drug: Ranibizumab 0.5
RxNorm normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab 0.5 mg with treatment aimed at resolution of all IRF only (relaxed arm: SRF tolerant)
Trial: 28530238
Drug: Duloxetine (AD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine (AD treatment)
Trial: 8929256
Drug: gemfibrozil 600
RxNorm normalized name: gemfibrozil 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemfibrozil 600 mg b.i.d.
Trial: 9466127
Drug: gemfibrozil 600
RxNorm normalized name: gemfibrozil 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemfibrozil 600 mg b.i.d. (in patients with > or = 20% reduction in triglyceride levels)
Trial: 8536013
Drug: Lidocaine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (5 ml intra-articular injection)
Trial: 8536013
Drug: Saline with
RxNorm normalized name: CVS Saline with Aloe Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline with contrast dye (5 ml intra-articular injection)
Trial: 3312048
Drug: Oral indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral indomethacin (IM)
Trial: 24428972
Drug: Corticosteroid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid treatment in SS asthma
Trial: 24428972
Drug: Corticosteroid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid treatment in SR asthma
Trial: 19939870
Drug: Bupropion XR
RxNorm normalized name: bupropion Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion XR 150 mg
Trial: 15979021
Drug: Venlafaxine XR
RxNorm normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Venlafaxine XR 75 mg
Trial: 12372663
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg of nicotine administered by nasal spray
Trial: 10411037
Drug: Sacral nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacral nerve stimulation (treatment group)
Trial: 7419336
Drug: 80 kcal-PSMF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 kcal-PSMF (17 g protein=2.6 g N)
Trial: 7419336
Drug: 180 kcal-PSMF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 kcal-PSMF (40 g protein=6.4 g N, 2 g fat)
Trial: 27667330
Drug: If participants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If participants who attempted vaccination had received the vaccine
Trial: 15635208
Drug: Treatment (face
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment (face immersion test)
Trial: 12878742
Drug: EGF enemas
RxNorm normalized name: ABX-EGF
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: EGF enemas (5 microg in 100 ml of inert carrier)
Trial: 8803527
Drug: 76 mg
RxNorm normalized name: menthol 76 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 76 mg disodium monofluorophosphate (MFP, equivalent to 10.0 mg F- ion)
Trial: 8803527
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg enteric-coated sodium fluoride (NaFor, equivalent of 11.3 mg F- ion)
Trial: 8803527
Drug: 22.1 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 22.1 mg sodium fluoride injection solution (NaFiv, equivalent to 10.0 mg F- ion)
Trial: 1728720
Drug: Insulin treatment
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin treatment (25 U fast-acting insulin bolus followed by continuous infusion of 1 U/kg body weight for 1 hour)
Trial: 6690344
Drug: sorbinil (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sorbinil (250 mg o.d.)
Trial: 6690344
Drug: sorbinil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sorbinil (5 mg/kg)
Trial: 30514364
Drug: Enriched flours
RxNorm normalized name: Flours
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enriched flours coupled with antibiotic treatment
Trial: 23156122
Drug: Nutrition counseling
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutrition counseling in the third trimester (education twice in the first month and once a month for the next 2 months)
Trial: 21082306
Drug: Low-dose chlorhexidine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose chlorhexidine solution (CHX)
Trial: 21082306
Drug: No chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No chlorhexidine solution (no CHX)
Trial: 15852426
Drug: Proton-pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton-pump inhibitor (PPI) therapy
Trial: 12769404
Drug: Topical colchicine
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical colchicine
Trial: 11783194
Drug: Jianruling (JRL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jianruling (JRL) treatment
Trial: 73353
Drug: nalbuphine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nalbuphine (0.1 mg/kg)
Trial: 1869004
Drug: pethidine (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pethidine (0.8 mg/kg)
Trial: 6741674
Drug: Alcohol (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (two doses)
Trial: 15889510
Drug: Medication (Control)
RxNorm normalized name: Medicated Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (Control)
Trial: 9327829
Drug: Vascular injury
RxNorm normalized name: acellular tissue engineered vessel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vascular injury treatment (angioplasty)
Trial: 7695066
Drug: Oral immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral immunotherapy (OIT) with birch pollen antigens in enterocoated capsules